Interrogating the haemodynamic effects of haemodialysis arteriovenous fistula on cardiac structure and function

Sokratis Stoumpos1,2*, Alastair Rankin1,2, Pauline Hall Barrientos3, Kenneth Mangion1,4, Ellon McGregor2, Peter C. Thomson2, Karen Stevenson2, Paul Welsh1, Ram Kasthuri3, David B. Kingsmore2, Giles Roditi3 & Patrick B. Mark1,2

Arteriovenous fistula (AVF) is the preferred type of vascular access for maintenance haemodialysis but it may contribute to maladaptive cardiovascular remodelling. We studied the effect of AVF creation on cardiac structure and function in patients with chronic kidney disease (CKD). In this prospective cohort study patients with CKD listed for first AVF creation underwent cardiac magnetic resonance (CMR) imaging at baseline and at 6 weeks. All participants had ultrasound measurements of fistula blood flow at 6 weeks. The primary outcome was the change in left ventricular (LV) mass. Secondary outcomes included changes in LV volumes, LV ejection fraction, cardiac output, LV global longitudinal strain and N-terminal-pro B-type natriuretic peptide (NT-proBNP). A total of 55 participants were enrolled, of whom 40 (mean age 59 years) had AVF creation and completed both scans. On the second CMR scan, a mean increase of 7.4 g (95% CI 1.1–13.7, p = 0.02) was observed in LV mass. Significant increases in LV end-diastolic volumes (p = 0.04) and cardiac output (p = 0.02) were also seen after AVF creation. No significant changes were observed in LV end-systolic volumes, LV ejection fraction, NT-proBNP and LV global longitudinal strain. In participants with fistula blood flows ≥ 600 mL/min (n = 22) the mean increase in LV mass was 15.5 g (95% CI 7.3–23.8) compared with a small decrease of 2.5 g (95% CI −10.6 to 5.6) in participants with blood flows < 600 mL/min (n = 18). Creation of AVF for haemodialysis resulted in a significant increase of LV myocardial mass within weeks after surgery, which was proportional to the fistula flow.

Establishment of a functioning arteriovenous fistula (AVF) has been the mainstay of haemodialysis (HD) treatment due to its durability, delivery of adequate solute clearance and low risk of infection. However, creation of an AVF is not benign and may have deleterious effects on cardiac structure and function1,2. Creation of an AVF establishes a shunt from the arterial to the venous circulation, and exposes the low pressure, high capacitance venous system to the high pressure, low capacitance arterial system. Immediately following creation, there is an associated increase in cardiac output and a decrease in subendocardial perfusion as a consequence of reduced systemic vascular resistance, increased myocardial contractility, and an increase in stroke volume and heart rate3,4. Over the following weeks, circulating blood volume increases in conjunction with increases in atrial and brain natriuretic peptides5,6. As the fistula increases in size and blood flow, there are further increases in left ventricular (LV) filling pressure and subsequent changes on atrial and ventricular chamber dimensions and function5,6,7. The physiological consequences may even progress till there is myocardial decompensation, left ventricle dilatation, and a decline in ejection fraction, eventually leading to LV hypertrophy (LVH) or heart failure1,7. All these changes are additive to underlying pre-existing LVH, dilatation, and dysfunction caused by progressive uremic cardiomyopathy and may be associated with adverse outcomes in dialysis patients8.

Maladaptive cardiac remodelling and, in particular, increased LV mass is an independent predictor of adverse cardiovascular events in CKD and has been used as a surrogate end point4. In the haemodialysis population, a study of adults with no history of congestive heart failure found that each 1 g/m² increment in LV mass index
was associated with a 62% increased risk of fatal and non-fatal cardiovascular events. Despite its detrimental effects when present, the impact of LVH regression on mortality remains uncertain. An elegant multifactorial interventional study by London et al. has demonstrated that a 10% decrease in LV mass translated into a 28% decrease in cardiovascular mortality over a 5-year period. Foley et al. found that improvements in LV mass over a 1-year period after the initiation of dialysis were associated with a reduced likelihood of cardiac failure but notably not with mortality risk. Patients particularly susceptible to these effects are the ones with pre-existing heart disease and high flow fistulas. Fistulas with flows exceeding 2 L/min and upper arm fistulas are traditionally at increased risk for the development of heart failure.

The effects of AVF creation on functional and structural cardiac parameters have been previously studied. Using cardiac magnetic resonance (CMR) imaging in 24 patients with CKD stage 5 undergoing fistula creation, Dundon et al. showed a mean increase of 13% in LV mass, 21% in LV end-systolic volumes, and 25% in cardiac output 6 months after AVF creation.

Typically, arteriovenous fistulas attain 40–60% of maximum blood flow within 1 day of creation, and reach their maximum flow as early as 6 weeks after creation. Parallel to the vascular remodelling in the fistula arm, a decrease in cardiovascular mortality over a 5-year period. Foley et al. found that improvements in LV mass effects when present, the impact of LVH regression on mortality remains uncertain. An elegant multifactorial interventional study by London et al. has demonstrated that a 10% decrease in LV mass translated into a 28% decrease in cardiovascular mortality over a 5-year period. Foley et al. found that improvements in LV mass over a 1-year period after the initiation of dialysis were associated with a reduced likelihood of cardiac failure but notably not with mortality risk. Patients particularly susceptible to these effects are the ones with pre-existing heart disease and high flow fistulas. Fistulas with flows exceeding 2 L/min and upper arm fistulas are traditionally at increased risk for the development of heart failure.

The aims of this study were two-fold: (i) to investigate myocardial changes early after AVF creation and (ii) to determine whether myocardial changes are proportional to the AVF blood flow. To address these questions, a prospective study using CMR imaging to evaluate changes on cardiac structure and function 6 weeks after AVF surgery in patients with advanced CKD was performed.

Results

Participant characteristics. From December 2, 2016, to August 20, 2018, 252 participants were screened and 55 were enrolled (Fig. 1). Of the 197 subjects who were excluded, 131 were found to be ineligible for the study. The reasons for exclusion included contraindications to MRI (n = 58), previous AV access surgery (n = 41), and frailty (n = 32) (Supplementary Table S1). Of the 49 participants who underwent the first CMR scan, 7 had no AVF surgery, and 2 withdrew consent, declining the second scan. In total, 40 participants completed the study and were included in the analysis of primary and secondary outcomes. Twenty-two had brachial artery flow rates ≥600 (1386 ± 785) mL/min and 18 had flows < 600 (266 ± 197) mL/min at 6 weeks (Fig. 1).

The baseline characteristics of the study participants are shown in Table 1. There were no differences between the 2 groups in the location of AVF, baseline eGFR, and antihypertensive medication use. Antiplatelet use was more common in the higher flow AVF group, and 3 subjects (all in the higher flow group) were started on antiplatelet therapy post-AVF surgery. The median duration between CMR scans in the higher flow group was 63 days (interquartile range 51–115 days) and in the lower flow group was 51 days (interquartile range 46–63 days; p = 0.14). Three participants started dialysis within the 6-week period between the two scans (all via central venous catheters). The baseline cardiac parameters of the 2 groups were well matched (Supplementary Table S2).

Primary outcome. The primary end point showed a mean increase of 7.4 g (95% CI 1.1–13.7, p = 0.02) in LV mass. To adjust for body surface area, change in LV mass index was also calculated. An increase of 5.1 g/m² (95% CI 1.6–8.6, p = 0.005) was found.

In the higher flow group the mean increase in LV mass was 15.6 g (95% CI 7.3–23.8) compared with a small decrease of 2.5 g (95% CI 10.6 to 5.6) in the lower flow group (p = 0.003 for comparison; Fig. 2). For the LV mass index the mean increase was 9.5 g/m² (95% CI 5.2–14.0) in the higher flow group compared with a small decrease of 0.3 g/m² (95% CI 5.2 to 4.6) in the lower flow group (p = 0.003 for comparison; Fig. 2).

Linear regression analyses undertaken showed that increase in the LV mass and LV mass index was more pronounced in subjects with higher flow fistulas (Fig. 3) and in subjects with lower LV mass at baseline (Supplementary Fig. S1). In the higher flow group, increase in LV mass was demonstrated in all except 2 subjects.

Secondary outcomes. Table 2 shows the changes observed for other ventricular indexes and atrial size, including LV end-diastolic volume, LV end-systolic volume, LV global longitudinal strain, cardiac output, cardiac index, LA volume, and septal thickness. The mean NT-proBNP levels for all subjects were elevated at baseline (Table 2) and increased further in the higher flow AVF group (p = 0.05 for comparison; Fig. 4). There was a drop in diastolic blood pressure between CMR scans (p = 0.03) but no changes in systolic blood pressure, body weight and haematocrit were observed (Table 2).

Discussion

In this prospective observational study we have examined the effect of AVF creation on LV mass in patients with advanced CKD using a high fidelity cardiac imaging modality (CMR). There was a substantial increase in LV mass observed on the second CMR scan after an average time of 6.3 weeks from AVF surgery. The effect was proportional to the brachial artery flow rate, with a 10.2% increase in LV mass in participants with flows exceeding 600 mL/min compared with a small decrease in those with lower blood flows. To the best of our knowledge this is the first study demonstrating such early changes in LV mass, linking the early AVF flow to the change in LV mass.

Arteriovenous fistula surgery is associated with adaptive cardiac remodelling necessary to accommodate the increase in cardiac output sufficient to service the fistula, whilst maintaining systemic blood supply. In a prospective study of 43 pre-dialysis patients, AVF formation resulted in a sustained reduction in arterial stiffness and
blood pressure as well as an increase in cardiac output and LV ejection fraction using echocardiography. In another prospective echocardiographic study of 47 patients, LV mass increased by 12.2 ± 32% one year post-AV access creation. With AVF creation, we observed a 4.8% increase in LV mass, 6.1% increase in LV end-diastolic volume, 8.7% increase in LA volume and 8.7% increase in cardiac output. In patients with fistula flows ≥ 600 mL/min, the increases were 10.2%, 8.7%, 14.7% and 13.9%, respectively, and there was also an increase in NT-proBNP levels. Linear regression analysis showed that increase in the LV mass and LV mass index was more pronounced in subjects with lower LV mass at baseline, and in the higher flow group, increase in LV mass was demonstrated in all except 2 subjects. There are no previous studies examining the cardiac changes shortly after AVF creation for comparisons of our findings.

The typical blood flow in the brachial artery is approximately 50 mL/min, which rapidly increases 10- to 20-folds after the fistula is created. Upper arm fistulas tend to have the highest blood flow rates and in fact, access flow has been shown to be up to twice as high in patients with a brachiocephalic compared to those with a radiocephalic AVF (40 vs 8%). In this study, 67% of the upper arm fistulas had flow rates exceeding 600 mL/min compared with 38% of the forearm fistulas and regression analysis showed that increases in the LV mass expectedly were proportional to the brachial artery flow.

Brain natriuretic peptide and its inactive N-terminal fragment have been studied extensively in patients with advanced CKD, and both markers have been shown to be strong predictors of cardiovascular morbidity and mortality. They are thought to be secreted in greater quantities in response to increases in myocardial wall stretch. Population-based studies suggest that plasma levels of brain natriuretic peptide and NT-proBNP are useful screening tests for heart failure and asymptomatic LV dysfunction. In a short-term prospective study of 16 CKD patients both atrial natriuretic peptide (ANP) and BNP levels were maximally increased (by 48% and 68%, respectively) 10 days after AVF creation. In another prospective study of 47 patients, plasma NT-proBNP levels increased by 170 ± 465% one year post-AV access creation. The cardiac structural changes coupled with a rise in validated biomarkers of cardiac remodelling, such as NT-proBNP, suggest that observed changes could translate into clinical outcomes. To this end, the significant increases in LV and LA volumes in keeping with a rise in NT-proBNP in the higher flow AVF group may add important prognostic information. In addition, the

Figure 1. Flowchart showing recruitment and arteriovenous fistula (AVF) groups.
Table 1. Characteristics of the study participants at baseline. AVF arteriovenous fistula, GFR glomerular filtration rate calculated using Chronic Kidney Disease Epidemiology Collaboration (CKD EPI) formula, ACEi angiotensin converting enzyme inhibitor, ARB angiotensin II receptor blocker. *Plus-minus values are mean ± SD. †Median (IQR). ‡Current or previous. ‡Includes 23 non-dialysis participants.

| Characteristic                                      | All (n = 40) | AVF flow ≥ 600 mL/min (n = 22) | AVF flow < 600 mL/min (n = 18) | p value |
|-----------------------------------------------------|--------------|--------------------------------|--------------------------------|---------|
| Age, years                                          | N/A          | N/A                            | N/A                            | 0.80    |
| Female sex, n (%)                                   | 19 (48)      | 9 (41)                         | 10 (56)                        | 0.53    |
| Time between first scan to AVF creation, days       | 9 (4–23)     | 14 (5–74)                      | 7 (2–17)                       | 0.13    |
| Time between first and second scan, days            | 58 (47–85)   | 63 (51–115)                    | 51 (46–63)                     | 0.14    |
| Time between AVF creation to second scan, days      | 44 (41–49)   | 45 (41–49)                     | 43 (41–46)                     | 0.60    |
| Diabetes mellitus, n (%)                            | 15 (38)      | 6 (27)                         | 9 (50)                         | 0.19    |
| Hypertension, n (%)                                  | 34 (85)      | 17 (77)                        | 17 (94)                        | 0.20    |
| Ischaemic heart disease, n (%)                       | 7 (18)       | 5 (23)                         | 2 (11)                         | 0.43    |
| Peripheral vascular disease, n (%)                  | 6 (15)       | 3 (14)                         | 3 (17)                         | 1.0     |
| Smoking, n (%)                                       | 22 (55)      | 12 (55)                        | 10 (56)                        | 1.0     |
| Location of AVF, n (%)                               | N/A          | N/A                            | N/A                            | 0.11    |
| Forearm AVF                                          | 16 (40)      | 6 (27)                         | 10 (56)                        | 0.56    |
| Upper arm AVF                                        | 24 (60)      | 16 (73)                        | 8 (44)                         | 0.13    |
| Serum creatinine, μmol/L                            | 458 ± 127    | 486 ± 140                      | 394 ± 56                       | 0.14    |
| Estimated GFR, mL/min/1.73 m²                        | 12 ± 3       | 11 ± 2                         | 13 ± 3                         | 0.24    |
| Dialysis, n (%)                                      | 17 (43)      | 7 (32)                         | 10 (56)                        | 0.20    |
| Medications, n (%)                                   | N/A          | N/A                            | N/A                            | 0.005   |
| ACEi or ARB                                          | 13 (33)      | 6 (27)                         | 7 (39)                         | 0.51    |
| Beta blocker                                         | 24 (60)      | 12 (55)                        | 12 (67)                        | 0.53    |
| Statin                                               | 25 (63)      | 16 (73)                        | 9 (50)                         | 0.19    |
| Aspirin or Clopidogrel                               | 19 (48)      | 15 (68)                        | 4 (22)                         | 0.005   |

Figure 2. Difference in the means of left ventricular (LV) mass (left) and LV mass index (right) between the 2 scans according to the brachial artery blood flow (p = 0.003 for the difference between groups). This figure shows the means in 40 subjects who completed the second cardiac magnetic resonance scan, 22 with blood flows ≥ 600 mL/min and 18 with blood flows < 600 mL/min. Change in means and the 95% CI show a significant statistical difference between groups (p = 0.003) with an independent t-test.
minimal changes in LV mass, chamber volumes and NT-proBNP in the lower flow group are physiologically plausible and further strengthen our findings.

A recent meta-analysis of 14 studies showed that creation of AVF leads to modest but significant decreases in blood pressure in patients with advanced CKD, with a preferential reduction in diastolic blood pressure. It is assumed that the reduction in diastolic blood pressure may have been related to changes in arterial compliance and drop in systemic vascular resistance resulting from the complex effects of the fistula-related haemodynamic changes. A decrease in diastolic but no significant change in systolic blood pressure was seen in this study cohort.

Figure 3. Effect of arteriovenous fistula (AVF) creation based on AVF blood flow. Linear regression analysis looking at change in LV mass (above) and LV mass index (below) in study participants with AVF creation. Increases in LV mass and LV mass index were more pronounced in those with higher fistula flows at 6 weeks after surgery.
However, this study was powered to observe the change in CMR-derived LV mass and was not specifically powered to study the changes in blood pressure. We have demonstrated that AVF creation may increase CMR-derived LV mass in patients with advanced CKD, particularly if ‘high flow’. Because of the short interval between the scans (median 8.3 weeks), the increase in LV mass observed is unlikely to be resulting from worsening of uraemia, plasma volume overload or changes in haematocrit and in fact serum creatinine, body weight and haematocrit did not change significantly between the scans. These results demonstrate that AVF creation, which is the cornerstone of haemodialysis treatment, has the potential to confer substantial cardiovascular risks in CKD patients, especially the ones with underlying cardiovascular disease. However, alternative vascular access choices have their own limitations. First, grafts are likely to induce similar haemodynamic changes and so may not reduce cardiovascular maladaptation. Second, catheters may have other risks, such as infection, that may result in adverse outcomes. Many unknowns remain, and several of those key questions were beyond the scope of this study. For example, baseline NT-proBNP levels, LV mass and LV mass index were higher in participants with blood flows < 600 mL/min, which is indicative of reduced LV compliance or “diastolic dysfunction”. A plausible alternative explanation of our findings is that cardiac stiffening and poor cardiac remodelling in this group resulted in lower AVF blood flows. Appropriately designed experimental studies are needed to infer causality. Also the long-term implications of the demonstrated changes in LV end-diastolic and LA volumes and BNP are unclear. Further work needs to be done to investigate whether they translate into adverse LV remodelling or systolic dysfunction and if so over what time period. Or whether they normalise with dialysis.

The strengths of this study include a prospective consecutive design, use of CMR as cardiac imaging modality, and standardised scanning protocols to limit variability. The study limitations included use of the modified Simpson’s method rather than the short axis stack of cines for estimation of LV parameters. We lack power and

### Table 2. Summary of changes in cardiac magnetic resonance-derived cardiac indexes, clinical and laboratory parameters. AVF arteriovenous fistula, LA left atrial, LV left ventricular, BP blood pressure, GFR glomerular filtration rate calculated using Chronic Kidney Disease Epidemiology Collaboration (CKD EPI) formula, NT-proBNP N-Terminal-pro B-type Natriuretic Peptide, hs-cTnI high-sensitivity cardiac Troponin I. *Plus-minus values are mean ± SD. †Includes 23 non-dialysis participants.

|                      | All (n = 40) | AVF flow ≥ 600 mL/min (n = 22) | AVF flow < 600 mL/min (n = 18) |
|----------------------|-------------|-------------------------------|-------------------------------|
| **Baseline**         |             | Baseline                       | Follow-up                     | Baseline                       | Follow-up                     |
| **LV mass, g**       | 154.4 ± 52.6* | 161.8 ± 50.2 0.02 | 152.4 ± 55.6* | <0.001 | 156.9 ± 50.2 | 154.4 ± 43.0 0.52 |
| **LV mass index, g/m²** | 83.7 ± 27.1 0.005 | 88.8 ± 26.2 | 80.8 ± 24.7 | 90.3 ± 24.7 | <0.001 | 87.3 ± 30.2 | 87.0 ± 28.6 0.91 |
| **LV end-diastolic volume, mL** | 155.8 ± 55.1 0.04 | 165.3 ± 49.6 | 167.5 ± 58.7 | 182.0 ± 54.5 | 0.03 | 141.5 ± 48.2 | 145.0 ± 34.2 0.61 |
| **LV end-systolic volume, mL** | 51.3 ± 27.6 0.12 | 55.4 ± 27.1 | 57.2 ± 31.7 | 63.5 ± 32.8 | 0.10 | 44.1 ± 20.0 | 45.5 ± 13.0 0.70 |
| **LV ejection fraction, %** | 67.9 ± 7.8 0.52 | 67.1 ± 7.2 | 66.7 ± 8.1 | 66.1 ± 7.4 | 0.66 | 69.2 ± 7.6 | 68.4 ± 7.0 0.65 |
| **LV cardiac output, L/min** | 6.9 ± 2.1 0.02 | 7.5 ± 2.0 | 7.2 ± 1.9 | 8.2 ± 1.9 | 0.007 | 6.5 ± 2.2 | 6.8 ± 1.8 0.61 |
| **LV cardiac index, L/min/m²** | 3.8 ± 1.1 0.009 | 4.2 ± 1.1 | 3.9 ± 1.0 | 4.5 ± 1.2 | 0.002 | 3.6 ± 1.1 | 3.8 ± 0.9 0.53 |
| **LV global longitudinal strain, %** | −15.3 ± 2.3 0.21 | −15.7 ± 2.5 | −15.9 ± 1.9 | −16.0 ± 2.0 | 0.93 | −14.5 ± 2.6 | −15.2 ± 3.1 0.04 |
| **LA volume, mL** | 85.9 ± 40.1 0.10 | 93.4 ± 34.7 | 86.6 ± 43.3 | 99.3 ± 37.8 | 0.05 | 84.9 ± 37.0 | 86.2 ± 30.1 0.85 |
| **LA volume index, mL/m²** | 46.9 ± 21.0 0.04 | 52.1 ± 20.0 | 46.6 ± 21.9 | 54.5 ± 19.9 | 0.03 | 47.3 ± 20.6 | 49.2 ± 20.4 0.59 |
| **Septal thickness, mm** | 9.0 ± 2.9 0.33 | 8.5 ± 2.9 | 8.5 ± 2.9 | 7.8 ± 3.0 | 0.23 | 9.5 ± 2.9 | 9.5 ± 2.6 0.90 |
| **Body weight, kg** | 74.7 ± 16.7 0.74 | 73.3 ± 15.2 | 75.3 ± 17.2 | 73.6 ± 15.2 | 0.76 | 73.9 ± 16.7 | 73 ± 15.7 0.89 |
| **Systolic BP, mmHg** | 154.3 ± 29.8 0.35 | 147 ± 30.0 | 149.8 ± 24.0 | 146.2 ± 21.1 | 0.64 | 160 ± 36.3 | 148.2 ± 39.7 0.43 |
| **Diastolic BP, mmHg** | 76.3 ± 13.9 0.03 | 69.4 ± 10.5 | 77.3 ± 14.9 | 70.2 ± 12.2 | 0.14 | 74.9 ± 12.9 | 68.4 ± 8.0 0.13 |
| **Hematocrit, %** | 32.7 ± 5.2 0.85 | 32.4 ± 4.3 | 32.0 ± 4.5 | 31.5 ± 4.0 | 0.70 | 33.4 ± 5.9 | 33.6 ± 4.5 0.93 |
| **Serum creatinine, μmol/L** | 458 ± 127 0.53 | 487 ± 161 | 486 ± 140 | 521 ± 180 | 0.59 | 394 ± 56 | 408 ± 53 0.65 |
| **Estimated GFR, mL/ min/1.73 m²** | 11.5 ± 2.6 0.25 | 10.3 ± 4.0 | 11.1 ± 2.3 | 9.5 ± 4.3 | 0.26 | 12.6 ± 3.0 | 11.9 ± 2.6 0.71 |
| **NT-proBNP, pg/mL** | 2390 ± 2513 0.08 | 314 ± 2360 | 1647 ± 1401 | 3174 ± 2439 | 0.02 | 2948 ± 3043 | 3069 ± 2408 0.82 |
| **hs-cTnI, pg/mL** | 13.1 ± 11.2 0.36 | 12.0 ± 9.1 | 12.4 ± 12.1 | 12.7 ± 8.9 | 0.89 | 13.7 ± 10.9 | 11.4 ± 9.6 0.21 |
follow-up duration to detect clinically significant outcomes, such as cardiovascular events and patient survival. Although the cohort was a single-center experience with a relatively small number of participants, our study group is representative of the typical CKD population referred for AVF creation. The right heart was not assessed, but the study was adequately powered to examine LV mass, which was our primary outcome. We have shown that AVF creation is associated with a significant increase in LV myocardial mass, cardiac chamber dimensions and NT-proBNP levels. The changes are more pronounced in higher blood flow arteriovenous fistulas. Although these surrogate markers are strongly associated with cardiovascular outcomes, the impact of AVF creation on clinical and mortality outcomes remains to be proved.

Methods

Study protocol. A prospective observational single-centre study was conducted between December 2, 2016, and August 20, 2018. The study protocol (http://dx.doi.org/10.36399/gla.pubs.215112) was approved by the institutional review board (North of Scotland Research Ethics Committee reference number, 16/NS/0099) and registered with ClinicalTrials.gov (NCT02997046). Written informed consent was obtained from all participants, and the studies were performed according to hospital guidelines for diagnostic procedures.

Study population. Pre-dialysis and dialysis patients (≥ 18 years of age) listed for creation of an autogenous forearm or upper arm AVF were eligible for enrollment. Dialysis patients were only included if they were dialysing via a tunneled catheter and had no prior permanent access. Consecutive patients with CKD who attended the outpatient renal clinics were screened for eligibility. Exclusion criteria were (a) standard contraindications to MRI, (b) frail, elderly or participants with multiple or serious comorbidities, and (c) previous arteriovenous access creation (autogenous or synthetic graft) in either or both arms. All participants had CMR imaging followed by MR angiography with relevance to research questions out with the present study.

Study procedures. Baseline CMR imaging was performed (3.0 T Prisma, Magnetom; Siemens Healthineers, Erlangen, Germany) before undergoing AVF creation. Repeat CMR and duplex ultrasound (US) of the fistula arm was conducted 6 weeks after the creation of AVF.

All scans were performed following a standardised protocol (online Data Supplement, Supplementary Fig. S2). Clinical history and blood tests were performed at the time of the first and second CMR scans. Analyses of CMR-derived LV mass and chamber volumes was performed offline by a research fellow (A.R.) trained in CMR reporting who was blinded to all clinical information and analysed anonymised images in a random order (Supplementary Table S3). The ipsilateral brachial artery flow rate was measured by an interventional radiologist with more than 20 years experience in fistula imaging (R.K.) using a Philips iU22 colour duplex scanner (Philips Healthcare, Bothell, WA, USA). Participants were categorised into 2 groups based on brachial artery flow rate (≥ 600 mL/min vs < 600 mL/min). The threshold of 600 mL/min was used as a surrogate of maturation based on the “rule of 6 s” in fistula assessment at 6 weeks. Brachial artery flows were assessed independently from the other cardiac parameters to ensure blinding. Serum N-terminal-pro B-type natriuretic peptide (NT-proBNP) and high-sensitivity cardiac Troponin I (hs-cTnI) were measured by immunoassays (Alere NT-proBNP and Stat high sensitive Troponin I, Architect, Abbott). Estimated glomerular filtration rate (eGFR) was calculated using
the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation. Information on the history of diabetes mellitus, hypertension, ischaemic heart disease, and peripheral vascular disease was obtained from the electronic patient records.

Outcomes. The primary outcome was change in CMR-derived LV mass in the total population. Secondary outcome measures included changes in LV end-diastolic and systolic volumes, left atrial (LA) volume, LV ejection fraction, cardiac output, cardiac index, LV global longitudinal strain, septal thickness, NT-proBNP, and hs-cTnI. Primary and secondary outcomes were also assessed for the blood flow subgroups.

Statistical analysis. The sample size was calculated using data from a single-arm pilot study involving CMR imaging prior to and 6 months following fistula creation that demonstrated increases in LV mass with AVF creation. Based on the increase in LV mass as the primary end point, power calculations (including accounting for a dropout rate of 15%) indicated that 49 subjects would provide a 7% difference in the LV mass from baseline to 6-week CMR with a power of > 80% and a 2-sided a level of 0.05 (online Data Supplement).

Descriptive statistics are expressed as means and standard deviations or medians and interquartile ranges for continuous measures as appropriate, and percentages are reported for categorical variables. We used independent sample t-tests and Pearson’s chi-squared tests to explore differences in baseline characteristics.

Independent t-tests were also used to compare the change in LV mass between the first and second scans for the total population and between the 2 groups. Two-sided tests were performed for all analyses, and the level of significance was set at p < 0.05. To estimate pre- versus post-AVF creation differences, the change between initial and subsequent measurements was calculated for each patient. The mean change was compared between the 2 groups with an unpaired t-test. For comparisons of non-normally distributed data, Wilcoxon rank-sum and Wilcoxon signed rank tests were used. All statistical analyses were conducted with Stata/SE Statistical Software, version 15.0 (StataCorp, College Station, Tex).

Received: 8 June 2021; Accepted: 25 August 2021
Published online: 13 September 2021

References
1. Iwashima, Y. et al. Effects of the creation of arteriovenous fistula for hemodialysis on cardiac function and natriuretic peptide levels in CRE. Am. J. Kidney Dis. 40(5), 974–982 (2002).
2. Basile, C. et al. The relationship between the flow of arteriovenous fistula and cardiac output in haemodialysis patients. Nephrol. Dial. Transplant. 23(1), 282–287 (2008).
3. Guyton, A. C. & Sagawa, K. Compensations of cardiac output and other circulatory functions in areflex dogs with large A-V fistulas. Am. J. Physiol. 200, 1157–1163 (1961).
4. Savage, M. T., Ferro, C. J., Sassano, A. & Tomson, C. R. The impact of arteriovenous fistula formation on central hemodynamic pressures in chronic renal failure patients: A prospective study. Am. J. Kidney Dis. 40(4), 753–759 (2002).
5. Ori, Y. et al. Haemodialysis arteriovenous access—A prospective haemodynamic evaluation. Nephrol. Dial. Transplant. 11(1), 94–97 (1996).
6. Parfrey, P. S. et al. Outcome and risk factors for left ventricular disorders in chronic uraemia. Nephrol. Dial. Transplant. 11(7), 1277–1283 (1996).
7. Ori, Y. et al. The contribution of an arteriovenous access for hemodialysis to left ventricular hypertrophy. Am. J. Kidney Dis. 40(4), 745–752 (2002).
8. Middleton, R. J., Parfrey, P. S. & Foley, R. N. Left ventricular hypertrophy in the renal patient. J. Am. Soc. Nephrol. 12(5), 1079–1084 (2001).
9. Zoccali, C. et al. Left ventricular mass monitoring in the follow-up of dialysis patients: Prognostic value of left ventricular hypertrophy progression. Kidney Int. 65(4), 1492–1498 (2004).
10. London, G. M. et al. Alterations of left ventricular hypertrophy in and survival of patients receiving hemodialysis: Follow-up of an interventional study. J. Am. Soc. Nephrol. 12(12), 2759–2767 (2001).
11. Foley, R. N. et al. Serial change in echocardiographic parameters and cardiac failure in end-stage renal disease. J. Am. Soc. Nephrol. 11(5), 912–916 (2000).
12. Martínez-Gallardo, R. et al. Congestive heart failure in patients with advanced chronic kidney disease: Association with pre-emptive vascular access placement. Nefrologia. 32(2), 206–212 (2012).
13. Schier, T., Göbel, G., Bösmüller, C., Gruber, I. & Tiefenthaler, M. Incidence of arteriovenous fistula closure due to high-output cardiac failure in kidney–transplanted patients. Clin. Transplant. 27(6), 858–865 (2013).
14. Wijnen, E. et al. The relation between vascular access flow and different types of vascular access with systemic hemodynamics in hemodialysis patients. Artif. Organs. 29(12), 960–964 (2005).
15. Dundon, B. K. et al. The deleterious effects of arteriovenous fistula-creation on the cardiovascular system: A longitudinal magnetic resonance imaging study. Int. J. Nephrol. Renovasc. Dis. 7, 337–345 (2014).
16. Begin, V., Ether, J., Dumont, M. & Leblanc, M. Prospective evaluation of the intra-access flow of recently created native arteriovenous fistulae. Am. J. Kidney Dis. 40(6), 1277–1282 (2002).
17. Lomonte, C. et al. Is there a place for duplex screening of the brachial artery in the maturation of arteriovenous fistulas?. Semin. Dial. 18(3), 243–246 (2005).
18. Korsheed, S., Eldenhi, M. T., John, S. G., Fluck, R. J. & McIntyre, C. W. Effects of arteriovenous fistula formation on arterial stiffness and cardiovascular performance and function. Nephrol. Dial. Transplant. 26(10), 3296–3302 (2011).
19. Hiremath, S. et al. Left ventricular growth after 1 year of haemodialysis does not correlate with arteriovenous access flow: A prospective cohort study. Nephrol. Dial. Transplant. 25(8), 2656–2661 (2010).
20. Khan, I. A. et al. N-terminal pro-B-type natriuretic peptide and B-type natriuretic peptide for identifying coronary artery disease and left ventricular hypertrophy in ambulatory chronic kidney disease patients. Am. J. Cardiol. 97(10), 1530–1534 (2006).
21. Zoccali, C. et al. Cardiac natriuretic peptides are related to left ventricular mass and function and predict mortality in dialysis patients. J. Am. Soc. Nephrol. 12(7), 1508–1515 (2001).
22. Wang, Y., Marshall, S. M., Thompson, M. G. & Hoenich, N. A. Cardiovascular risk in patients with end-stage renal disease: A potential role for advanced glycation end products. Contrib. Nephrol. 149, 168–174 (2005).
23. de Lemos, J. A. et al. Multimodality strategy for cardiovascular risk assessment: Performance in 2 population-based cohorts. Circulation 135(22), 2119–2132 (2017).
24. Scholz, S. S. et al. Effects of arteriovenous fistula on blood pressure in patients with end-stage renal disease: A systematic meta-analysis. J. Am. Heart Assoc. 8(4), e011183 (2019).
25. Mathew, R. O. et al. Effect of arteriovenous fistula creation on systolic and diastolic blood pressure in patients with pre-dialysis advanced chronic kidney disease. Am. J. Hypertens. 32(9), 858–867 (2019).
26. Cokkinos, D. V. & Belogianneas, C. Left ventricular remodelling: A problem in search of solutions. Eur. Cardiol. 11(1), 29–35 (2016).
27. Stoumpos, S. et al. Ferumoxytol MR angiography versus duplex US for vascular mapping before arteriovenous fistula surgery for hemodialysis. Radiology 297(1), 214–222 (2020).
28. Vascular Access 2006 Work Group. Vascular Access 2006 Work Group, Clinical practice guidelines for vascular access. Am. J. Kidney Dis. 48(Suppl 1), S176-247 (2006).
29. Levey, A. S. et al. A new equation to estimate glomerular filtration rate. Ann. Intern. Med. 150(9), 604–612 (2009).

Author contributions
S.S., D.K., G.R. and P.M. conceptualised and designed the study. S.S., A.R., P.H.B., K.M., E.M.G., P.T., R.K., P.W., K.S. and P.M. analysed and interpreted the data. S.S. drafted the paper. All authors read and approved the final manuscript.

Funding
The study was funded by the endowment fund of the Glasgow Renal & Transplant Unit.

Competing interests
The authors declare no competing interests.

Additional information
Supplementary Information The online version contains supplementary material available at https://doi.org/10.1038/s41598-021-97625-5.
Correspondence and requests for materials should be addressed to S.S.

Reprints and permissions information is available at www.nature.com/reprints.

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2021